Approved by the Food and Drug Administration (FDA) in 2010, sipuleucel-T was the first personalised “cancer vaccine” to treat prostate cancer in the metastatic, non-symptomatic population of 30,000 men in the US. Sipuleucel-T is prepared individually for each patient and infused in three sessions over one-month. In 2015, sipuleucel-T’s owner, Dendreon, filed for bankruptcy. This search aimed to review how this innovative product failed to achieve commercial success.